Navigation Links
Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
Date:8/5/2009

dates to prove safe and effective for treatment of non-small cell lung cancer, ovarian cancer, non-Hodgkin's lymphoma, and sarcoma or to achieve market acceptance for such treatments, the possibility that priority review will not be granted by the FDA for the pixantrone NDA and that a decision by the FDA is not rendered in late 2009, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling OPAXIO, pixantrone, and brostallicin, and the risk factors listed or described from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, we do not intend to update or alter our forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    F: 206.272.4434
    E: deramian@ctiseattle.com
    www.celltherapeutics.com/media.htm

    Investors Contact:
    Ed Bell
    T: 206.282.7100
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
   http://www.celltherapeutics.com/investors

                              Cell Therapeutics, Inc.

                  Condensed Consolidated Statements of Operations
                   (In thousands, except for per share amounts)
                                    (unaudited)

                              Three Months Ended       Six Months Ended
                                    June 30,                June 30,
                                    --------                --------
                                2009        
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Budding Biomedical Scientists , ... School participated in the Scientific Enrichment and ... School of Medicine . , The ... professional experience in the sciences and brings them ... and students for both academic and career mentoring. ...
(Date:8/26/2014)... 2014 The 20 ambassadors representing the ... community issued the following statement on Facebook today regarding ... driving new funding specifically for ALS research: , “Who ... some ice would raise all this awareness and funding ... and on behalf of the entire ALS community, would ...
(Date:8/26/2014)...  ViveBio, LLC a leading provider of products ... announced today that it has signed a distribution ... Knoxville, Tennessee to distribute ... United States . ViveST is the first ... biological specimen transport systems.  The technology enables easy, ...
(Date:8/26/2014)... (PRWEB) August 26, 2014 Genedata, ... drug discovery and life science research, today announced ... will be held in Asia, Europe, and ... global pharmaceutical companies and leading research organizations will ... best practices, case studies, and upcoming challenges in ...
Breaking Biology Technology:Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3
... Presented at 21st North American Cystic Fibrosis ... Findings in Adult population -, SOUTH PLAINFIELD, ... Inc.,(PTC), a biopharmaceutical company focused on the discovery, ... today announced encouraging data,from a Phase 2 clinical ...
... RIDGE, N.J., Oct. 5 VioQuest,Pharmaceuticals (OTC Bulletin ... acquiring, developing and,commercializing targeted cancer therapeutics, announced today ... Thursday, October 11, 2007 at 2:00 p.m.,Pacific Time ... Room in San Francisco.,Daniel Greenleaf, VioQuest,s president and ...
... SOMERSET, N.J., Oct. 5 Alfacell Corporation,(Nasdaq: ACEL ... call and,Webcast at 11 a.m. EDT on Monday, Oct. ... executive officer, and Lawrence A. Kenyon,executive vice president, chief ... Alfacell,s financial performance for the fiscal,fourth quarter and year ...
Cached Biology Technology:PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 2PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 3PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 4PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 5VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 3Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast 2
(Date:8/27/2014)... Africa is entering what is described by the Volunteer ... The Eastern Cape provincial government warned residents in ... strong winds and veld fires. A high veld ... and along the coast in the Great Kei and ... regions, and during thunderstorms. The thunderstorms bring lightning ...
(Date:8/27/2014)... deadly disease that exists as five strains, none of ... strains is the Sudan ebolavirus (SUDV). Although not the ... illness, even as recently as 2012. In a new ... , researchers now report a possible therapy that could ... Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain that ...
(Date:8/27/2014)... Thousands of fishing traps are lost or abandoned each ... as derelict traps, which continue to catch fish, crabs, ... in losses to habitat, fisheries, and the watermen who ... to a newly published NOAA study. , The report, ... the first of its kind to examine the derelict ...
Breaking Biology News(10 mins):Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2
... A person,s ability to battle viruses at the cellular ... prions misfold and cluster native proteins to cause disease, ... marks the first discovery of so-called "good" prion-like proteins ... proteins involved in innate immunity: the way the body ...
... University professor is helping students improve their confidence ... learning. Candice Shoemaker, professor of horticulture, has ... and self-efficacy. Self-efficacy involves student confidence in understanding ... learning and achievement. Shoemaker,s published research appeared in ...
... be a leading cause of the decline of coral reefs ... Georgia have found that extreme low temperatures affect certain corals ... potentially catastrophic consequences for coral ecosystems. Their findings appear in ... Biology . Lead author Dustin Kemp, a postdoctoral associate ...
Cached Biology News:'Good' prion-like proteins boost immune response, UT Southwestern scientists report 2Finding their way: Study shows connection between academic direction and student learning 2Finding their way: Study shows connection between academic direction and student learning 3Study: Severe low temperatures devastate coral reefs in Florida Keys 2Study: Severe low temperatures devastate coral reefs in Florida Keys 3
... Have you bought a Perkin Elmer UltraVIEW system ... the Andor iXon and iQ software? No problem. ... upgrade. You keep your existing microscope, lasers, Sutter ... customise it to work with our precision controller ...
...
... is a 96-well ELISA-compatible plate (containing 12 x ... Monoclonal Antibody is immobilized by a method that ... the tail fiber protein of the T7 bacteriophage. ... 10 9 phage per well and low ...
... The TRAPeze RT Telomerase Detection ... in vitro assay for the ... quantification of telomerase activity. It ... TRAPeze assay and adds the ...
Biology Products: